Fund moves
0.9%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VSTM · NASDAQ · Pharmaceutical Preparations
Verastem (VSTM) · oqro.io/stocks/VSTM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Verastem was filed in the last 90 days. The latest on record was on Dec 4, 2020.
Since 2012, Verastem insiders reported 104 open-market purchases and 164 sales on Forms 4 and 5, with purchases in 8 different years, most recently 2020.
In the last 90 days, 2 insiders of Verastem (VSTM) reported 4 open-market sales worth $386K in total on SEC Form 4. The largest seller by value was Dan Paterson, with $365K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Verastem (VSTM) was disclosed by a member of Congress in the last 12 months.
Verastem's next results are expected on Mar 2, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$6.33−0.53 (−7.73%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−35.5% (−$3.48) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $9.81 on Nov 20, 2025 to $6.33 on Nov 20, 2026 (−35.5%). Disclosed in this range: 0 insider trades, 32 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Needham, Ma.
Last 12 months
−35.5%
Market value
$866M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 19.7M shares sold short (14.4% of shares outstanding), +14.3% vs the previous count, 5.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$30.9M
+209.1% vs the year before
Net income, fiscal 2025
−$209M
A loss for the year
Shares outstanding
126M
As of Nov 2, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Dan Paterson (President and CEO) sold ~$353K of Verastem
Automatic salePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Verastem over the 12 months to Nov 20, 2026: 8 clinical trials.
Top officer leaving
“Paterson notified the Board of Directors (the “Board”) of the Company of his decision to retire as President and Chief Executive Officer of the Company, effective January 1, 2027 (the “Effective Date”).”
2 insiders sold ~$374K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Verastem reported 104 open-market purchases and 164 sales since 2012; purchases in 8 different years, most recently 2020.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $619K12×12 trades |
| 2025 | — | $1.33M46×46 trades |
| 2024 | — | $275K40×40 trades |
| 2023 | — | $56K34×34 trades |
| 2022 | — | $253K25×25 trades |
| 2021 | — | $68K3×3 trades |
| 2020 | $109K1×1 trade | $5.22M2×2 trades |
| 2019 | $106K1×1 trade | — |
| 2018 | $281K14×14 trades | — |
| 2017 | $320K3×3 trades | — |
| 2015 | $8.29M8×8 trades | $24K2×2 trades |
| 2014 | $693K22×22 trades | — |
| 2013 | $2.36M45×45 trades | — |
| 2012 | $8.15M10×10 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Nobody is above 5% on the latest filings: every recent filer has reported going below the line.
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by software from the filings listed below · Oct 19, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeAgainst the S&P 500 over the year
Since Nov 14, 2025, VSTM is down 9.1% and the index fund is up 8.7%: 18 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much VSTM moves
Beta 1.1 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 247 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Latest annual report filed Mar 4, 2026. Read the filing
The risk factor headings of this report could not be read with confidence, so none are shown. They are in the filing.
From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We do not believe we are currently party to any pending legal action, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business or operating results.
Source: SEC EDGAR, Form 10-K filed Mar 4, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
1 active phase 3 trial and 9 active phase 2 trials led by this company, mostly in low grade ovarian serous adenocarcinoma, low grade serous ovarian cancer, non small cell lung cancer. The ones with the nearest registered primary completion date still ahead:
4 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the U.S., the first treatment specifically FDA-approved for adults with KRAS mutated recurrent LGSOC who have received prior systemic therapy. AVMAPKI FAKZYNJA CO-PACK received accelerated approval in the U.S. on May 8, 2025. We are also conducting RAMP 301, a Phase 3 trial designed to evaluate avutometinib plus defactinib versus Investigator’s Choice of Treatment (“ICT”) in patients with recurrent LGSOC with and without a KRAS mutation. This trial will serve as a confirmatory study for the initial U.S.
And 10 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 4, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Last results
Oct 14, 2026
More than 30 days ago
Next results, expected
Mar 2, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
3%
3 of 96 insider purchases since 2012 came within 30 days after a results announcement
From Verastem's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Verastem's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
2 certified in FY2026 Q3, vs 0 a year earlier. 2 positions in total, median offered wage $173K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Revenue
$24M
+113.6% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $173M, at Sep 30, 2026
Net income, last 12 months
−$179M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 14, 2026.
Revenue and earnings history, 15 fiscal yearsEarnings dates and the stock's moves
Fails to deliver: 148K shares (about $1.2M) were not delivered on time for settlement on Oct 9, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 42.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (18.8% on ATS, 23.5% with other brokers), close to its 26-week average of 40.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (15.2%), UBS ATS (10.5%), SIGMA X2 (7.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.